Understanding Patient Equity & RSV Immuno-Prophylaxis

Time: 3:00 pm
day: Pre-Conference Focus Day: Respiratory Infectious Disease Vaccine Development

Details:

• Direct cost benefit of immuno-prophylaxis driven solely by savings from a reduction in RSV hospitalizations
• Better understanding the cost/risk of the use of monoclonals and vaccines in pregnant women